abstract: Clonal cytogenetic abnormalities have been reported among 30-80% of patients with myelodysplastic syndromes (MDS); however, 20-70% of patients with MDS show a normal karyotype that may nevertheless harbour a cryptic genetic alteration. Earlier reports have suggested that the distribution of specific chromosomal aberrations varies among Western and Asian countries, with geographical and ethnic differences in the frequency of specific chromosomal aberrations. This article compared the cytogenetic data of 36 adult Omani patients with MDS to previously reported data from other populations. Differences were noted between the percentages of clonal aberrations and the median age of Omani subjects at presentation in comparison to individuals of different ethnicities and from various geographical locations. To the best of the authors' knowledge, this is the first report to describe the cytogenetic data of patients with MDS from Oman.
M yelodysplastic syndromes (mds) are a group of clonal haematopoietic stem cell diseases characterised by cytopaenia, dysplasia in one or more of the major myeloid cell lines, ineffective haematopoiesis and an increased risk of developing acute myeloid leukaemia (AML). 1 Cytogenetic and molecular abnormalities are key elements in the diagnosis of MDS. Clonal chromosomal abnormalities in MDS have been observed in 30-80% of patients, depending on the subtype and whether it is de novo or mutageninduced. 2, 3 For the other 20-70% of MDS patients with normal karyotypes, there is substantial evidence for the presence of submicroscopic alterations-such as point mutations, microdeletions, microamplifications, epigenetic changes or copy number neutral loss of information-which may form the genetic basis of the disease. [4] [5] [6] The percentage of clonal abnormalities in the literature varies between 23-78%. [7] [8] [9] Over time, MDS has been increasingly recognised as a cause of bone marrow failure; however, the precise incidence of de novo MDS is unknown. 10 Jacobs et al. have suggested that the distribution of specific chromosomal aberrations in MDS varies between Western and Asian countries. 11 Another report also indicated geographical and ethnic differences in the frequency of specific chromosomal aberrations.
in Indian population has been reported to vary from 37.5-88%. 13 In addition, the frequency of chromosomal abnormalities varies between 37-50% in China, Thailand, Hong Kong and Japan. 13, 14 Complex aberrations have been more frequently observed in Indian patients as compared to those from other Asian countries. 13 As such, ethnic and/or geographical differences could be heterogeneous and contribute to clinical, cytogenetic or molecular events leading to MDS. Available reports on the incidence of MDS mostly originate from European countries, although major studies have been conducted in Japan. [15] [16] [17] [18] [19] [20] [21] [22] To the best of the authors' knowledge, this is the first report detailing the cytogenetic profile of Omani patients with MDS. In order to analyse ethno-geographical differences in the pathogenesis of MDS, the current article aimed to compare the cytogenetic findings of Omani patients with de novo MDS with available data from Europe, North and South America, Africa and other Asian countries.
Methods
Data were collected from all patients with MDS presenting between 2006-2013 to the Department of Haematology at the Sultan Qaboos University Hospital (SQUH), a tertiary care centre in Muscat, Oman. A diagnosis of MDS was made as per the criteria of the World Health Organization (WHO). 23 Patients who did not fulfill the WHO criteria were excluded. All eligible subjects subsequently had their peripheral blood count recorded. In addition, bone marrow samples were obtained prior to the initiation of any therapy.
Cytogenetic analysis of the bone marrow samples was performed using GTG banding, with karyotypes reported according to the International System for Human Cytogenomic Nomenclature. 24 At least 20 metaphases were karyotyped and analysed from 24-and 48-hour bone marrow cultures. Clonal Table 1 ]. The median follow-up period was 28 months (range: 3-70 months). Table 2 shows the distribution of MDS subtypes according to age and gender.
Overall, 26 patients (72.2%) had normal karyotypes which indicated a good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) [ Table 3 ]. 25 One patient had a normal variant and another had a non-clonal abnormality. Eight patients had abnormal karyotypes (22.2%), of which two patients had clones which had trisomy 8 and one patient each had trisomy 21, a del(5)(q15q31) abnormality, a del(11)(q23) abnormality, an i(17)(q10) abnormality, a del(18)(p11) abnormality and an absent Y chromosome [ Table 4 ]. Six of these eight patients also showed normal clones along with abnormal clones.
Comparison of Omani Data with Other Populations
The characteristics of Omani patients with MDS were compared to those previously reported from other populations [ Table 5] . 3, 7, 11, 13, 15, 16, 22, [26] [27] [28] [29] [30] [31] [32] [33] The median age of patients with MDS in Oman (65 years old) was lower than that reported from Europe (65-74 years old) but was higher compared to other Asian countries (50-60 years old). 10, 13, 15, 17, [19] [20] [21] [22] 26, 28, 31 The median age of the patients in Tunisia was 60 years old. 22 Brazilian patients had the youngest median age (29 years old). 27 Among Omani patients, the male-to-female ratio was 1:1, which was in accordance with a sample from Thailand and close to ratios reported from Brazil (1.2:1) and Germany (1.3:1); 3, 26, 27 however, this finding was contrary to many other Asian countries and certain European, North American and African countries in which males outnumbered females. 7, 11, 13, 15, 22, 28, 30, 31 Further research is needed to determine a possible cause for this gender difference between populations.
The majority of Omani patients showed normal karyotypes (62.2%) and were believed to have a good prognosis according to IPSS-R classifications. 25 Only published data on the frequency of abnormal karyotypes from Japan (23.9%) and China (37.1%) were close to the data from Oman. 16, 28 Chromosomal abnormalities such as i(17q), trisomy 21 and the absence of the Y chromosome were seen in one each of the Omani patients (2.8% each). Studies from Germany, Japan and Argentina also reported patients with loss of the Y chromosome (7.0%, 1.1% and 2.7%, respectively); 3, 15, 29 however, this abnormality was not observed among patients from Thailand, Switzerland or Brazil. 7, 26, 27 Similarly, trisomy 21 was not observed Patients with abnormal karyotypes, n (%) G m id è n e e t a l. Le e et al . 31 (1 99 9)
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26 (19 98 ) in Thailand or India. 13, 26 The USA had the lowest percentage of AML transformation (2.8%), followed by Korea (16.8%) and Oman (19.4%). 31 The overall percentage of abnormal karyotypes was lower among Omanis compared to other populations (22.2% versus 23.9-68.8%), although this may be due to the low number of patients included in the Omani sample. 3, 7, 11, 13, 15, 16, 22, [26] [27] [28] [29] [30] [31] [32] [33] The highest percentage of patients with abnormal karyotypes was reported from Brazil. 27 The frequency of cytogenetic abnormalities according to MDS subtype was found to be different among Omani patients when compared to other populations, with most Omani patients having normal karyotypes and thus a good prognosis. 3, 7, 11, 13, 15, 16, 22, [26] [27] [28] [29] [30] [31] [32] [33] The current research sought to compare the cytogenetic characteristics of Omani patients with MDS to those reported among other geographic/ ethnic populations. A review of the literature revealed that this dataset constitutes the first report from an ethnic Omani population. However, verification of the findings of this research is needed with a larger sample. As the native Omani population is relatively small, numbering approximately 2.35 million in 2015, the number of patients with MDS presenting to SQUH was hence limited and the sample size too small to draw statistically significant conclusions. 34 As such, it is recommended that the sample size be increased in future studies. Socioeconomic characteristics and access to the healthcare system may also contribute to MDS awareness and detection rates within a given population. The referral of suspected patients from rural healthcare centres to tertiary hospitals for cytogenetic testing could also increase the detection/confirmation of MDS markers for better characterisation.
Conclusion
To the best of the authors' knowledge, this report is the first from an Omani population detailing the cytogenetic characteristics of patients with MDS. These data may serve as a basis for further research in Oman and a comparison with other populations. c o n f l i c t o f i n t e r e s t
